-
1
-
-
79955069103
-
Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management
-
SUTER LG, FRAENKEL L, BRAITHWAITE RS: Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management. Arch Intern Med 2011;171:657-67.
-
(2011)
Arch Intern Med
, vol.171
, pp. 657-667
-
-
Suter, L.G.1
Fraenkel, L.2
Braithwaite, R.S.3
-
2
-
-
23644456726
-
An evaluation of the decision tree format of the american college of rheumatology 1987 classification criteria for rheumatoid arthritis: Performance over five years in a primary care-based prospective study
-
LUNT M, SYMMONS DP, SILMAN AJ: An evaluation of the decision tree format of the american college of rheumatology 1987 classification criteria for rheumatoid arthritis: Performance over five years in a primary care-based prospective study. Arthritis Rheum 2005;52:2277-83.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 2277-2283
-
-
Lunt, M.1
Symmons, D.P.2
Silman, A.J.3
-
3
-
-
79952471147
-
Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting
-
HALLINEN TA, SOINI EJ, EKLUND K, PUOLAKKA K: Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology (Oxford) 2010;49:767-77.
-
(2010)
Rheumatology (Oxford)
, vol.49
, pp. 767-777
-
-
Hallinen, T.A.1
Soini, E.J.2
Eklund, K.3
Puolakka, K.4
-
4
-
-
79959436349
-
Treatment strategies aiming at remission in early rheumatoid arthritis patients: Starting with methotrexate monotherapy is cost-effective
-
SCHIPPER LG, KIEVIT W, DEN BROEDER AA et al.: Treatment strategies aiming at remission in early rheumatoid arthritis patients: Starting with methotrexate monotherapy is cost-effective. Rheumatology (Oxford) 2011;50:1320-30.
-
(2011)
Rheumatology (Oxford)
, vol.50
, pp. 1320-1330
-
-
Schipper, L.G.1
Kievit, W.2
Den Broeder, A.A.3
-
5
-
-
61549117187
-
Cost-effectiveness modeling of abatacept versus other biologic agents in dmards and anti-tnf inadequate responders for the management of moderate to severe rheumatoid arthritis
-
RUSSELL A, BERESNIAK A, BESSETTE L et al.: Cost-effectiveness modeling of abatacept versus other biologic agents in dmards and anti-tnf inadequate responders for the management of moderate to severe rheumatoid arthritis. Clin Rheumatol 2009;28:403-12
-
(2009)
Clin Rheumatol
, vol.28
, pp. 403-412
-
-
Russell, A.1
Beresniak, A.2
Bessette, L.3
-
6
-
-
79952396885
-
Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in france
-
SARAUX A, GOSSEC L, GOUPILLE P et al.: Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in france. Rheumatology (Oxford) 2010;49:733-40.
-
(2010)
Rheumatology (Oxford)
, vol.49
, pp. 733-740
-
-
Saraux, A.1
Gossec, L.2
Goupille, P.3
-
7
-
-
80055081129
-
Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in italy: A modelling approach
-
CIMMINO MA, LEARDINI G, SALAFFI F et al.: Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in italy: A modelling approach. Clin Exp Rheumatol 2011;29:633-41
-
(2011)
Clin Exp Rheumatol
, vol.29
, pp. 633-641
-
-
Cimmino, M.A.1
Leardini, G.2
Salaffi, F.3
-
8
-
-
84856153028
-
Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain
-
BERESNIAK A, ARIZA-ARIZA R, GARCIA-LLORENTE JF, RAMIREZ-ARELLANO A, DUPONT D: Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain. Int J Inflam 2011;2011:727634.
-
(2011)
Int J Inflam
, vol.2011
, pp. 727634
-
-
Beresniak, A.1
Ariza-Ariza, R.2
Garcia-Llorente, J.F.3
Ramirez-Arellano, A.4
Dupont, D.5
-
9
-
-
84860681286
-
Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in finland
-
PUOLAKKA K, BLÅFIELD H, KAUPPI M et al.: Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in finland. Open Rheumatol J 2012;6:38-43.
-
(2012)
Open Rheumatol J
, vol.6
, pp. 38-43
-
-
Puolakka, K.1
Blåfield, H.2
Kauppi, M.3
-
10
-
-
84855451722
-
International cohort study of 73 antiku-positive patients: Association of p70/p80 anti-ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis
-
LAKOTA K, THALLINGER GG, SODIN-SEMRL S et al.: International cohort study of 73 antiku-positive patients: Association of p70/p80 anti-ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis. Arthritis Res Ther 2012;14:R2.
-
(2012)
Arthritis Res Ther
, vol.14
-
-
Lakota, K.1
Thallinger, G.G.2
Sodin-Semrl, S.3
-
11
-
-
0142135697
-
Direct medical costs and their predictors in patients with rheumatoid arthritis: A threeyear study of 7, 527 patients
-
MICHAUD K, MESSER J, CHOI HK, WOLFE F: Direct medical costs and their predictors in patients with rheumatoid arthritis: A threeyear study of 7, 527 patients. Arthritis Rheum 2003;48:2750-62.
-
(2003)
Arthritis Rheum
, vol.48
, pp. 2750-2762
-
-
Michaud, K.1
Messer, J.2
Choi, H.K.3
Wolfe, F.4
-
12
-
-
0023881198
-
The importance of age, education, and comorbidity in the substantial earnings losses of individuals with symmetric polyarthritis
-
MITCHELL JM, BURKHAUSER RV, PINCUS T: The importance of age, education, and comorbidity in the substantial earnings losses of individuals with symmetric polyarthritis. Arthritis Rheum 1988;31:348-57.
-
(1988)
Arthritis Rheum
, vol.31
, pp. 348-357
-
-
Mitchell, J.M.1
Burkhauser, R.V.2
Pincus, T.3
-
13
-
-
84862165188
-
Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: An application of bayesian methods for evidence synthesis in a markov model
-
NGUYEN CM, BOUNTHAVONG M, MENDES MA et al.: Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: An application of bayesian methods for evidence synthesis in a markov model. Pharmacoeconomics 2012;30:575-93.
-
(2012)
Pharmacoeconomics
, vol.30
, pp. 575-593
-
-
Nguyen, C.M.1
Bounthavong, M.2
Mendes, M.A.3
-
14
-
-
84860333083
-
Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis
-
STAHL EA, WEGMANN D, TRYNKA G et al.: Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat Genet 2012;44:483-9.
-
(2012)
Nat Genet
, vol.44
, pp. 483-489
-
-
Stahl, E.A.1
Wegmann, D.2
Trynka, G.3
-
15
-
-
77956386199
-
Clustering rash results: A novel method for developing rheumatoid arthritis states for use in valuation studies
-
MCTAGGART-COWAN HM, BRAZIER JE, TSUCHIYA A: Clustering rash results: A novel method for developing rheumatoid arthritis states for use in valuation studies. Value Health 2010;13:787-95.
-
(2010)
Value Health
, vol.13
, pp. 787-795
-
-
McTaggart-Cowan, H.M.1
Brazier, J.E.2
Tsuchiya, A.3
-
16
-
-
69849101948
-
Introduction to neural networks in health care
-
Harvard
-
SORDO M: Introduction to neural networks in health care. Open Clinical 2002; Harvard: 1-17.
-
(2002)
Open Clinical
, pp. 1-17
-
-
Sordo, M.1
-
17
-
-
34748898307
-
Developing a neural network model for health care
-
NOLTING J: Developing a neural network model for health care. AMIA Annu Symp Proc 2006:1049.
-
(2006)
AMIA Annu Symp Proc
, pp. 1049
-
-
Nolting, J.1
-
18
-
-
33846524203
-
Predictive role of diagnostic information in treatment efficacy of rheumatoid arthritis based on neural network model analysis
-
ZHA QL, HE YT, YAN XP et al.: Predictive role of diagnostic information in treatment efficacy of rheumatoid arthritis based on neural network model analysis. Zhong Xi Yi Jie He Xue Bao 2007;5:32-8.
-
(2007)
Zhong Xi Yi Jie He Xue Bao
, vol.5
, pp. 32-38
-
-
Zha, Q.L.1
He, Y.T.2
Yan, X.P.3
-
19
-
-
1542647357
-
Neural network approach to medical grading of rheumatoid arthritis
-
ZHOU Z, MAO Z, DENG Z: Neural network approach to medical grading of rheumatoid arthritis. Sheng Wu Yi Xue Gong Cheng Xue ZaZhi 1999;16:479-82.
-
(1999)
Sheng Wu Yi Xue Gong Cheng Xue ZaZhi
, vol.16
, pp. 479-482
-
-
Zhou, Z.1
Mao, Z.2
Deng, Z.3
-
20
-
-
33749355349
-
Qalys: Are they helpful to decision makers?
-
MC GREGOR M, CARO JJ: Qalys: Are they helpful to decision makers? Pharmacoeconomics 2006;24:947-52.
-
(2006)
Pharmacoeconomics
, vol.24
, pp. 947-952
-
-
McGregor, M.1
Caro, J.J.2
-
21
-
-
35948995784
-
Advantages and limitations of utility assessment methods in rheumatoid arthritis
-
BERESNIAK A, RUSSELL AS, HARAOUI B, BESSETTE L, BOMBARDIER C, DURU G: Advantages and limitations of utility assessment methods in rheumatoid arthritis. J Rheumatol 2007;34:2193-200.
-
(2007)
J Rheumatol
, vol.34
, pp. 2193-2200
-
-
Beresniak, A.1
Russell, A.S.2
Haraoui, B.3
Bessette, L.4
Bombardier, C.5
Duru, G.6
-
22
-
-
79956064523
-
Is there an international backlash against cost-utility analysis?
-
RAMSEY S: Is there an international backlash against cost-utility analysis? ISPOR Connections 2010;16:3.
-
(2010)
ISPOR Connections
, vol.16
, pp. 3
-
-
Ramsey, S.1
-
23
-
-
0036073935
-
Limitations of the methods used for calculating qualityadjusted life-year values
-
DURU G, AURAY JP, BERESNIAK A, LAMURE M, PAINE A, NICOLOYANNIS N: Limitations of the methods used for calculating qualityadjusted life-year values. Pharmacoeconomics 2002;20:463-73.
-
(2002)
Pharmacoeconomics
, vol.20
, pp. 463-473
-
-
Duru, G.1
Auray, J.P.2
Beresniak, A.3
Lamure, M.4
Paine, A.5
Nicoloyannis, N.6
-
24
-
-
84858124911
-
Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderateto-severe rheumatoid arthritis
-
SOINI EJ, HALLINEN TA, PUOLAKKA K, VIHERVAARA V, KAUPPI MJ: Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderateto-severe rheumatoid arthritis. J Med Econ 2012;15:340-51.
-
(2012)
J Med Econ
, vol.15
, pp. 340-351
-
-
Soini, E.J.1
Hallinen, T.A.2
Puolakka, K.3
Vihervaara, V.4
Kauppi, M.J.5
-
25
-
-
80155157726
-
Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment
-
KOBELT G, LEKANDER I, LANG A, RAFFEINER B, BOTSIOS C, GEBOREK P: Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. Int J Technol Assess Health Care 2011;27:193-200.
-
(2011)
Int J Technol Assess Health Care
, vol.27
, pp. 193-200
-
-
Kobelt, G.1
Lekander, I.2
Lang, A.3
Raffeiner, B.4
Botsios, C.5
Geborek, P.6
-
26
-
-
79961125179
-
Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis
-
TOSH JC, WAILOO AJ, SCOTT DL, DEIGHTON CM: Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis. J Rheumatol 2011;38:1593-600.
-
(2011)
J Rheumatol
, vol.38
, pp. 1593-1600
-
-
Tosh, J.C.1
Wailoo, A.J.2
Scott, D.L.3
Deighton, C.M.4
|